Evommune, Inc. (EVMN)

Market Cap	918.83M
Revenue (ttm)	13.00M +85.7%
Net Income	-68.87M
EPS	-11.22
Shares Out	36.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	357,455
Open	28.50
Previous Close	28.65
Day's Range	25.42 - 28.82
52-Week Range	13.89 - 33.20
Beta	n/a
Analysts	Strong Buy
Price Target	43.88 (+72.01%)
Earnings Date	May 7, 2026

About EVMN

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2025
• Employees: 48
• Stock Exchange: NYSE
• Ticker Symbol: EVMN
• Website: https://www.evommune.com

Financial Performance

In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for EVMN stock is "Strong Buy." The 12-month stock price target is $43.88, which is an increase of 72.01% from the latest price.

Price Target

$43.88

(72.01% upside)

Analyst Consensus: Strong Buy